The Phase 3 Clinical Trial for Visceral Fat Atrophy with Tesamorelin.

Journal Context: The New England Journal of Medicine | Identifiers: DOI: 10.1056/NEJMoa1006044 / PMID: 21121834

Principal Investigators: Falutz, J., Allas, S., Blotner, S., Kotler, D., Grinspoon, S., et al. (Theratechnologies / Harvard Medical School)

Methodology: A multi-center, randomized, double-blind, placebo-controlled Phase 3 human trial enrolling 412 adult patients presenting with severe visceral adiposity and metabolic lipodystrophy. Subjects received daily bedtime subcutaneous injections of $2\text{ mg}$ of Tesamorelin over a 26-week cycle. Changes in body composition were precisely tracked via computed tomography (CT) scans.

Key Findings: Tesamorelin therapy produced a highly targeted metabolic shift. Active cohorts achieved a statistically significant $-15.2\%$ reduction in visceral adipose tissue (VAT), deeply melting hidden deep-belly fat layers without causing loss of beneficial subcutaneous fat or lean muscle mass. This lipolytic effect directly correlated with optimized endogenous IGF-1 generation and a broad reduction in overall triglyceride profiles.